Harrow acquires eye drug TYRVAYA for up to $100M
Harrow announced the close of its $30M acquisition of TYRVAYA, a dry eye nasal spray, which it expects to add its growing ocular surface franchise. The deal includes up to $70M in milestone payments.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed